Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

Pile of papers on a desk

Launching in the February issue of Nature Reviews Immunology, the Preprint Watch column is designed to provide rapid and open access to early data on both COVID-19 and non-COVID-19 immunology preprints. The first two reviews are: Super(antigen) target for SARS-CoV-2 and Sensing our Z-RNA.

During the COVID-19 pandemic the pace of scientific discovery and the race to find solutions required swift communication of results and fuelled an increase in immunology preprints. Journal club communities around the world seized the opportunity to evaluate and critically analyse a large number of SARS-CoV-2 preprints to provide independent insights to frontline researchers, to the general public, and to help prevent misinformation.

The journal group at Precision Immunology Institute at the Icahn School of Medicine, New York, and the OxImmuno Literature Initiative at the University of Oxford were both producing regular preprint summaries related to the COVID-19 emergency. Towards the end of 2020, the journal club teams from both institutes joined forces to launch the Oxford-Mount Sinai (OxMS) preprint journal club. During a weekly virtual joint ‘journal club’ they discuss selected preprints using their cross-institutional expertise and find the latest advancement in immunology. This new way of assessing and reviewing preprint literature may become a new approach to academic peer reviewing.

The full story is available on the Nuffied Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS) website

 

 

 

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Regular meat consumption linked with a wide range of common diseases

Research

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.